MedPath

Alvesco

These highlights do not include all the information needed to use ALVESCO safely and effectively. See full prescribing information for ALVESCO. Initial U.S. Approval: 2006

Approved
Approval ID

9f6112fb-78ef-43cf-8ae3-36370eb45468

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Feb 16, 2023

Manufacturers
FDA

Covis Pharma US, Inc

DUNS: 118094829

Products 2

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

ciclesonide

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code70515-712
Application NumberNDA021658
Product Classification
M
Marketing Category
C73594
G
Generic Name
ciclesonide
Product Specifications
Route of AdministrationRESPIRATORY (INHALATION)
Effective DateDecember 19, 2022
FDA Product Classification

INGREDIENTS (3)

CICLESONIDEActive
Quantity: 160 ug in 1 1
Code: S59502J185
Classification: ACTIB
ALCOHOLInactive
Code: 3K9958V90M
Classification: IACT
NORFLURANEInactive
Code: DH9E53K1Y8
Classification: IACT

ciclesonide

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code70515-711
Application NumberNDA021658
Product Classification
M
Marketing Category
C73594
G
Generic Name
ciclesonide
Product Specifications
Route of AdministrationRESPIRATORY (INHALATION)
Effective DateDecember 19, 2022
FDA Product Classification

INGREDIENTS (3)

CICLESONIDEActive
Quantity: 80 ug in 1 1
Code: S59502J185
Classification: ACTIB
NORFLURANEInactive
Code: DH9E53K1Y8
Classification: IACT
ALCOHOLInactive
Code: 3K9958V90M
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.